Imsidolimab: an emerging biological therapy for generalized pustular psoriasis
- PMID: 37079741
- DOI: 10.1093/bjd/ljad128
Imsidolimab: an emerging biological therapy for generalized pustular psoriasis
Conflict of interest statement
Conflicts of interest D.G. has received educational support from Lilly. S.K.M. reports departmental income from AbbVie, Almirall, Eli Lilly, Janssen-Cilag, Novartis, Sanofi and UCB, outside the submitted work.
Comment on
-
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial.Br J Dermatol. 2023 Jul 17;189(2):161-169. doi: 10.1093/bjd/ljad083. Br J Dermatol. 2023. PMID: 37120722 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
